Osteoporosis is a systemic skeletal disease characterized by low bone mineral density (BMD) and deterioration of bone architecture, resulting in reduced bone strength and, consequently, increased susceptibility to fractures which poses a significant public health concern worldwide, particularly in aging populations [1]. The health-economic impact of vertebral and hip fractures has been extensively explored and it is well known that these fractures are associated with morbidity/disability and increased mortality; they also account for a substantial portion of the direct fracture costs. This review aims to provide a comprehensive overview of osteoporosis, including its pathophysiology, risk factors, diagnostic approaches, and management strategies. By elucidating the multifaceted nature of this condition, healthcare providers can better identify individuals at risk, implement preventive measures, and optimize treatment to reduce the burden of osteoporotic fractures.
References
[1]
NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy (2001) Osteoporosis Prevention, Diagnosis, and Therapy. JAMA, 285, 785-795. https://doi.org/10.1001/jama.285.6.785
[2]
Kanis, J.A. (1994) Assessment of Fracture Risk and Its Application to Screening for Postmenopausal Osteoporosis: Synopsis of a WHO Report. Osteoporosis International, 4, 368-381. https://doi.org/10.1007/BF01622200
[3]
Sànchez-Riera, L. and Wilson, N. (2017) Fragility Fractures & Their Impact on Older People. Best Practice & Research Clinical Rheumatology, 31, 169-191. https://doi.org/10.1016/j.berh.2017.10.001
[4]
Adachi, J.D., Loannidis, G., Berger, C., Joseph, L., Papaioannou, A., Pickard, L., Papadimitropoulos, E.A., Hopman, W., Poliquin, S., Prior, J.C., Hanley, D.A., Olszynski, W.P., Anastassiades, T., Brown, J.P., Murray, T., Jackson, S.A., Tenenhouse, A. and Canadian Multicentre Osteoporosis Study (CaMos) Research Group (2001) The Influence of Osteoporotic Fractures on Health-Related Quality of Life in Community-Dwelling Men and Women across Canada. Osteoporosis International, 12, 903-908. https://doi.org/10.1007/s001980170017
[5]
Brenneman, S.K., Barrett-Connor, E., Sajjan, S., Markson, L.E. and Siris, E.S. (2006) Impact of Recent Fracture on Health-Related Quality of Life in Postmenopausal Women. Journal of Bone and Mineral Research, 21, 809-816. https://doi.org/10.1359/jbmr.060301
[6]
Brown, J.P., Adachi, J.D., Schemitsch, E., Tarride, J.E., Brown, V., Bell, A., Reiner, M., Oliveira, T., Motsepe-Ditshego, P., Burke, N. and Slatkovska, L. (2021) Mortality in Older Adults Following a Fragility Fracture: Real-World Retrospective Matched-Cohort Study in Ontario. BMC Musculoskeletal Disorders, 22, Article No. 105. https://doi.org/10.1186/s12891-021-03960-z
[7]
Tarride, J.É., Adachi, J.D., Brown, J.P., Schemitsch, E., Slatkovska, L. and Burke, N. (2021) Incremental Costs of Fragility Fractures: A Population-Based Matched-Cohort Study from Ontario, Canada. Osteoporosis International, 32, 1753-1761. https://doi.org/10.1007/s00198-021-05877-8
[8]
Burge, R., Dawson-Hughes, B., Solomon, D.H., Wong, J.B., King, A. and Tosteson, A. (2007) Incidence and Economic Burden of Osteoporosis-Related Fractures in the United States, 2005-2025. Journal of Bone and Mineral Research, 22, 465-475. https://doi.org/10.1359/jbmr.061113
[9]
Feng, X. and McDonald, J.M. (2011) Disorders of Bone Remodeling. Annual Review of Pathology: Mechanisms of Disease, 6, 121-145. https://doi.org/10.1146/annurev-pathol-011110-130203
[10]
Pouresmaeili, F., Kamalidehghan, B., Kamarehei, M. and Goh, Y.M. (2018) A Comprehensive Overview on Osteoporosis and Its Risk Factors. Therapeutics and Clinical Risk Management, 14, 2029-2049. https://doi.org/10.2147/TCRM.S138000
[11]
Bessette, L., Ste-Marie, L.G., Jean, S., Davison, K.S., Beaulieu, M., Baranci, M., Bessant, J. and Brown, J.P. (2008) The Care Gap in Diagnosis and Treatment of Women with a Fragility Fracture. Osteoporosis International, 19, 79-86. https://doi.org/10.1007/s00198-007-0426-9
[12]
US Preventive Services Task Force, Curry, S.J., Krist, A.H., Owens, D.K., Barry, M.J., Caughey, A.B., Davidson, K.W., Doubeni, C.A., Epling Jr., J.W., Kemper, A.R., Kubik, M., Landefeld, C.S., Mangione, C.M., Phipps, M.G., Pignone, M., Silverstein, M., Simon, M.A., Tseng, C.W. and Wong, J.B. (2018) Screening for Osteoporosis to Prevent Fractures: US Preventive Services Task Force Recommendation Statement. JAMA, 319, 2521-2531. https://doi.org/10.1001/jama.2018.7498
[13]
McCloskey, E., Kanis, J.A., Johansson, H., Harvey, N., Odén, A., Cooper, A., Cooper, C., Francis, R.M., Reid, D.M., Marsh, D., Selby, P., Thompson, F., Hewitt, S. and Compston, J. (2015) FRAX-Based Assessment and Intervention Thresholds—An Exploration of Thresholds in Women Aged 50 Years and Older in the UK. Osteoporosis International, 26, 2091-2099. https://doi.org/10.1007/s00198-015-3176-0
[14]
Compston, J., Cooper, A., Cooper, C., Gittoes, N., Gregson, C., Harvey, N., Hope, S., Kanis, J.A., McCloskey, E.V., Poole, K.E.S., Reid, D.M., Selby, P., Thompson, F., Thurston, A., Vine, N. and National Osteoporosis Guideline Group (NOGG) (2017) UK Clinical Guideline for the Prevention and Treatment of Osteoporosis. Archives of Osteoporosis, 12, Article No. 43. https://doi.org/10.1007/s11657-017-0324-5
[15]
Goel, H., Binkley, N., Boggild, M., Chan, W.P., Leslie, W.D., McCloskey, E., Morgan, S.L., Silva, B.C. and Cheung, A.M. (2024) Clinical Use of Trabecular Bone Score: The 2023 ISCD Official Positions. Journal of Clinical Densitometry, 27, Article ID: 101452. https://doi.org/10.1016/j.jocd.2023.101452
[16]
Mazzetti, G., Berger, C., Leslie, W.D., Hans, D., Langsetmo, L., Hanley, D.A., Kovacs, C.S., Prior, J.C., Kaiser, S.M., Davison, K.S., Josse, R., Papaioannou, A., Adachi, J.R., Goltzman, D., Morin, S.N. and CaMos Research Group (2017) Densitometer-Specific Differences in the Correlation Between Body Mass Index and Lumbar Spine Trabecular Bone Score. Journal of Clinical Densitometry, 20, 233-238. https://doi.org/10.1016/j.jocd.2016.11.003
[17]
LeBoff, M.S., Greenspan, S.L., Insogna, K.L., Lewiecki, E.M., Saag, K.G., Singer, A.J. and Siris, E.S. (2022) The Clinician’s Guide to Prevention and Treatment of Osteoporosis. Osteoporosis International, 33, 2049-2102. https://doi.org/10.1007/s00198-021-05900-y
[18]
Institute of Medicine (US) Committee to Review Dietary Reference Intakes for Vitamin D and Calcium, Ross, A.C., Taylor, C.L., Yaktine, A.L. and Del Valle, H.B. (2011) Dietary Reference Intakes for Calcium and Vitamin D. National Academies Press, Washington DC.
[19]
Ross, A.C., Manson, J.E., Abrams, S.A., Aloia, J.F., Brannon, P.M., Clinton, S.K., Durazo-Arvizu, R.A., Gallagher, J.C., Gallo, R.L., Jones, G., Kovacs, C.S., Mayne, S.T., Rosen, C.J. and Shapses, S.A. (2011) The 2011 Dietary Reference Intakes for Calcium and Vitamin D: What Dietetics Practitioners Need to Know. Journal of the Academy of Nutrition and Dietetics, 111, 524-527. https://doi.org/10.1016/j.jada.2011.01.004
[20]
Ayo-Yusuf, O.A. and Olutola, B.G. (2014) Epidemiological Association between Osteoporosis and Combined Smoking and Use of Snuff among South African Women. Nigerian Journal of Clinical Practice, 17, 174-177. https://doi.org/10.4103/1119-3077.127542
[21]
Mikosch, P. (2014) Alcohol and Bone. Wiener Medizinische Wochenschrift, 164, 15-24. https://doi.org/10.1007/s10354-013-0258-5
[22]
Burrows, M. (2007) Exercise and Bone Mineral Accrual in Children and Adolescents. Journal of Sports Science and Medicine, 6, 305-312.
[23]
De Souto Barreto, P., Rolland, Y., Vellas, B. and Maltais, M. (2019) Association of Long-Term Exercise Training with Risk of Falls, Fractures, Hospitalizations, and Mortality in Older Adults: A Systematic Review and Meta-Analysis. JAMA Internal Medicine, 179, 394-405. https://doi.org/10.1001/jamainternmed.2018.5406
[24]
Miller, P.D., Pannacciulli, N., Malouf-Sierra, J., Singer, A., Czerwiński, E., Bone, H.G., Wang, C., Huang, S., Chines, A., Lems, W. and Brown, J.P. (2020) Efficacy and Safety of Denosumab vs. Bisphosphonates in Postmenopausal Women Previously Treated with Oral Bisphosphonates. Osteoporosis International, 31, 181-191. https://doi.org/10.1007/s00198-019-05233-x
[25]
Eastell, R., Rosen, C.J., Black, D.M., Cheung, A.M., Murad, M.H. and Shoback, D. (2019) Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism, 104, 1595-1622. https://doi.org/10.1210/jc.2019-00221
[26]
Black, D.M., Cummings, S.R., Karpf, D.B., Cauley, J.A., Thompson, D.E., Nevitt, M.C., Bauer, D.C., Genant, H.K., Haskell, W.L., Marcus, R., Ott, S.M., Torner, J.C., Quandt, S.A., Reiss, T.F. and Ensrud, K.E. (1996) Randomised Trial of Effect of Alendronate on Risk of Fracture in Women with Existing Vertebral Fractures. Fracture Intervention Trial Research Group. Lancet, 348, 1535-1541. https://doi.org/10.1016/S0140-6736(96)07088-2
[27]
Barrionuevo, P., Kapoor, E., Asi, N., Alahdab, F., Mohammed, K., Benkhadra, K., Almasri, J., Farah, W., Sarigianni, M., Muthusamy, K., Al Nofal, A., Haydour, Q., Wang, Z. and Murad, M.H. (2019) Efficacy of Pharmacological Therapies for the Prevention of Fractures in Postmenopausal Women: A Network Meta-Analysis. The Journal of Clinical Endocrinology & Metabolism, 104, 1623-1630. https://doi.org/10.1210/jc.2019-00192
[28]
Chesnut III, C.H., Skag, A., Christiansen, C., Recker, R., Stakkestad, J.A., Hoiseth, A., Felsenberg, D., Huss, H., Gilbride, J., Schimmer, R.C., Delmas, P.D. and Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE) (2004) Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis. Journal of Bone and Mineral Research, 19, 1241-1249. https://doi.org/10.1359/JBMR.040325
[29]
Black, D.M., Delmas, P.D., Eastell, R., Reid, I.R., Boonen, S., Cauley, J.A., Cosman, F., Lakatos, P., Leung, P.C., Man, Z., Mautalen, C., Mesenbrink, P., Hu, H., Caminis, J., Tong, K., Rosario-Jansen, T., Krasnow, J., Hue, T.F., Sellmeyer, D., Eriksen, E.F., Cummings, S.R. and HORIZON Pivotal Fracture Trial (2007) Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis. The New England Journal of Medicine, 356, 1809-1822. https://doi.org/10.1056/NEJMoa067312
[30]
Boonen, S., Reginster, J.Y., Kaufman, J.M., Lippuner, K., Zanchetta, J., Langdahl, B., Rizzoli, R., Lipschitz, S., Dimai, H.P., Witvrouw, R., Eriksen, E., Brixen, K., Russo, L., Claessens, F., Papanastasiou, P., Antunez, O., Su, G., Bucci-Rechtweg, C., Hruska, J., Incera, E., Vanderschueren, D. and Orwoll, E. (2012) Fracture Risk and Zoledronic Acid Therapy in Men with Osteoporosis. The New England Journal of Medicine, 367, 1714-1723. https://doi.org/10.1056/NEJMoa1204061
[31]
Bone, H.G., Bolognese, M.A., Yuen, C.K., Kendler, D.L., Miller, P.D., Yang, Y.C., Grazette, L., San Martin, J. and Gallagher, J.C. (2011) Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass. The Journal of Clinical Endocrinology & Metabolism, 96, 972-980. https://doi.org/10.1210/jc.2010-1502
[32]
Freemantle, N., Satram-Hoang, S., Tang, E.T., Kaur, P., Macarios, D., Siddhanti, S., Borenstein, J., Kendler, D.L. and DAPS Investigators (2012) Final Results of the DAPS (Denosumab Adherence Preference Satisfaction) Study: A 24-Month, Randomized, Crossover Comparison with Alendronate in Postmenopausal Women. Osteoporosis International, 23, 317-326. https://doi.org/10.1007/s00198-011-1780-1
[33]
Sølling, A.S., Harsløf, T. and Langdahl, B. (2020) Treatment with Zoledronate Subsequent to Denosumab in Osteoporosis: A Randomized Trial. Journal of Bone and Mineral Research, 35, 1858-1870. https://doi.org/10.1002/jbmr.4098
[34]
Cummings, S.R., Ferrari, S., Eastell, R., Gilchrist, N., Jensen, J.B., McClung, M., Roux, C., Törring, O., Valter, I., Wang, A.T. and Brown, J.P. (2018) Vertebral Fractures after Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension. Journal of Bone and Mineral Research, 33, 190-198. https://doi.org/10.1002/jbmr.3337
[35]
Riddle, R.C. (2023) Endocrine Functions of Sclerostin. Current Opinion in Endocrine and Metabolic Research, 28, Article ID: 100433. https://doi.org/10.1016/j.coemr.2022.100433
[36]
Cosman, F., Crittenden, D.B., Adachi, J.D., Binkley, N., Czerwinski, E., Ferrari, S., Hofbauer, L.C., Lau, E., Lewiecki, E.M., Miyauchi, A., Zerbini, C.A., Milmont, C.E., Chen, L., Maddox, J., Meisner, P.D., Libanati, C. and Grauer, A. (2016) Romosozumab Treatment in Postmenopausal Women with Osteoporosis. The New England Journal of Medicine, 375, 1532-1543. https://doi.org/10.1056/NEJMoa1607948
[37]
Qaseem, A., Hicks, L.A., Etxeandia-Ikobaltzeta, I., Shamliyan, T., Cooney, T.G. and Clinical Guidelines Committee of the American College of Physicians, Cross Jr., J.T., Fitterman, N., Lin, J.S., Maroto, M., Obley, A.J., Tice, J.A. and Tufte, J.E. (2023) Pharmacologic Treatment of Primary Osteoporosis or Low Bone Mass to Prevent Fractures in Adults: A Living Clinical Guideline from the American College of Physicians. Annals of Internal Medicine, 176, 224-238. https://doi.org/10.7326/M22-1034
[38]
Saag, K.G., Shane, E., Boonen, S., Marín, F., Donley, D.W., Taylor, K.A., Dalsky, G.P. and Marcus, R. (2007) Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis. The New England Journal of Medicine, 357, 2028-2039. https://doi.org/10.1056/NEJMoa071408
[39]
Neer, R.M., Arnaud, C.D., Zanchetta, J.R., Prince, R., Gaich, G.A., Reginster, J.Y., Hodsman, A.B., Eriksen, E.F., Ish-Shalom, S., Genant, H.K., Wang, O. and Mitlak, B.H. (2001) Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis. The New England Journal of Medicine, 344, 1434-1441. https://doi.org/10.1056/NEJM200105103441904
[40]
Kendler, D.L., Marin, F., Zerbini, C.A.F., Russo, L.A., Greenspan, S.L., Zikan, V., Bagur, A., Malouf-Sierra, J., Lakatos, P., Fahrleitner-Pammer, A., Lespessailles, E., Minisola, S., Body, J.J., Geusens, P., Möricke, R. and López-Romero, P. (2018) Effects of Teriparatide and Risedronate on New Fractures in Post-Menopausal Women with Severe Osteoporosis (VERO): A Multicentre, Double-Blind, Double-Dummy, Randomised Controlled Trial. Lancet, 391, 230-240. https://doi.org/10.1016/S0140-6736(17)32137-2
[41]
Miller, P.D., Hattersley, G., Riis, B.J., Williams, G.C., Lau, E., Russo, L.A., Alexandersen, P., Zerbini, C.A., Hu, M.Y., Harris, A.G., Fitzpatrick, L.A., Cosman, F., Christiansen, C. and ACTIVE Study Investigators (2016) Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women with Osteoporosis: A Randomized Clinical Trial. JAMA, 316, 722-733. https://doi.org/10.1001/jama.2016.11136
[42]
Cosman, F., Miller, P.D., Williams, G.C., Hattersley, G., Hu, M.Y., Valter, I., Fitzpatrick, L.A., Riis, B.J., Christiansen, C., Bilezikian, J.P. and Black, D. (2017) Eighteen Months of Treatment with Subcutaneous Abaloparatide Followed by 6 Months of Treatment with Alendronate in Postmenopausal Women with Osteoporosis: Results of the ACTIVExtend Trial. Mayo Clinic Proceedings, 92, 200-210. https://doi.org/10.1016/j.mayocp.2016.10.009
[43]
Rossouw, J.E., Anderson, G.L., Prentice, R.L., LaCroix, A.Z., Kooperberg, C., Stefanick, M.L., Jackson, R.D., Beresford, S.A., Howard, B.V., Johnson, K.C., Kotchen, J.M., Ockene, J. and Writing Group for The Women’s Health Initiative Investigators (2002) Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From The Women’s Health Initiative Randomized Controlled Trial. JAMA, 288, 321-333. https://doi.org/10.1001/jama.288.3.321
[44]
Crandall, C.J., Hovey, K.M., Andrews, C., Cauley, J.A., Stefanick, M., Shufelt, C., Prentice, R.L., Kaunitz, A.M., Eaton, C., Wactawski-Wende, J. and Manson, J.E. (2017) Comparison of Clinical Outcomes among Users of Oral and Transdermal Estrogen Therapy in The Women’s Health Initiative Observational Study. Menopause, 24, 1145-1153. https://doi.org/10.1097/GME.0000000000000899
[45]
Manson, J.E., Allison, M.A., Rossouw, J.E., Carr, J.J., Langer, R.D., Hsia, J., Kuller, L.H., Cochrane, B.B., Hunt, J.R., Ludlam, S.E., Pettinger, M.B., Gass, M., Margolis, K.L., Nathan, L., Ockene, J.K., Prentice, R.L., Robbins, J., Stefanick, M.L. and WHI and WHI-CACS Investigators (2007) Estrogen Therapy and Coronary-Artery Calcification. The New England Journal of Medicine, 356, 2591-2602. https://doi.org/10.1056/NEJMoa071513
[46]
The NAMS 2017 Hormone Therapy Position Statement Advisory Panel (2017) The 2017 Hormone Therapy Position Statement of the North American Menopause Society. Menopause, 24, 728-753. https://doi.org/10.1097/GME.0000000000000921
[47]
Cobin, R.H., Goodman, N.F. and AACE Reproductive Endocrinology Scientific Committee (2017) American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on Menopause—2017 Update. Endocrine Practice, 23, 869-880. https://doi.org/10.4158/EP171828.PS
[48]
US Preventive Services Task Force, Mangione, C.M., Barry, M.J., Nicholson, W.K., Cabana, M., Caughey, A.B., Chelmow, D., Coker, T.R., Davis, E.M., Donahue, K.E., Jaén, C.R., Kubik, M., Li, L., Ogedegbe, G., Pbert, L., Ruiz, J.M., Stevermer, J. and Wong, J.B. (2022) Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Persons: US Preventive Services Task Force Recommendation Statement. JAMA, 328, 1740-1746. https://doi.org/10.1001/jama.2022.18625
[49]
Gennari, L., Merlotti, D. and Nuti, R. (2010) Selective Estrogen Receptor Modulator (SERM) for the Treatment of Osteoporosis in Postmenopausal Women: Focus on Lasofoxifene. Clinical Interventions in Aging, 5, 19-29. https://doi.org/10.2147/CIA.S6083
[50]
Lindsay, R., Gallagher, J.C., Kagan, R., Pickar, J.H. and Constantine, G. (2009) Efficacy of Tissue-Selective Estrogen Complex of Bazedoxifene/Conjugated Estrogens for Osteoporosis Prevention in At-Risk Postmenopausal Women. Fertility and Sterility, 92, 1045-1052. https://doi.org/10.1016/j.fertnstert.2009.02.093
[51]
Srivastava, M. and Deal, C. (2002) Osteoporosis in Elderly: Prevention and Treatment. Clinics in Geriatric Medicine, 18, 529-555. https://doi.org/10.1016/S0749-0690(02)00022-8
